During July 30 - August 1, 2024, ADLM 2024 (formerly AACC) was unveiled in McCormick Place Convention Center, Chicago. Zybio at booth 4617 received thousands of visits to our Core Lab Solution and Precision Diagnostic Solution. We are honored to have the appreciation and trust of our partners and healthcare professionals, which, in turn, motivate Zybio team to be further dedicated to facilitating laboratory diagnostics with our nine platforms constantly upgrading and launching new products. 

At booth 4617 at ADLM 2024, Zybio exhibited the Core Lab Solution and Precision Diagnostic Solution with its flagships from eight product platforms, including Hematology (EXZ6000pro, Z50, Z4 VET), Urinalysis (U3600, U2610, U1600), Coagulation (YX-2000), Chemistry (EXC400, EXC200), CLIA (EXI 1800), POCT (EXR 110, Q8 pro), Molecular (EXM3000, EXP160) and Microbiology (EXS2600, EXB120).

Zybio’s Core Lab Solution, designed to streamline laboratory testing from rapid screening to accurate measurement of biomarkers, is equipped with state-of-the-art instruments from Hematology, Urinalysis, Coagulation, Chemistry, CLIA to POCT. Each platform enjoys several new products with better performance launched in recent years and witnesses continuous upgrading of reliability and function design. Based on flexibly integration of instruments of various throughput, the customizable Core Laboratory Solution can be an ideal fit for laboratories of various scales. 

With strategic planning for precision diagnostics in early years since Zybio’s founding, Zybio’s continuous input in research and development made molecular and microbiological detection equipment accessible to healthcare professional worldwide. During ADLM 2024, Zybio demonstrated the Precision Diagnostic Solution with Zybio’s flagships in molecular extraction EXM3000, molecular testing EXP 160, MALDI-TOF MS EXS2600 and blood culture EXB120. Zybio’s Precision Diagnostic Solution played a vital role in controlling the COVID-19 pandemic, and has been recognized by more and more professionals globally. 

Furthermore, Zybio has 4 abstract posters successfully submitted to ADLM and be published as a supplement issue in ADLM’s Clinical Chemistry, and the Performance Evaluation of the Zybio EXT 4800: A Novel Optical-Magnetic Coagulation Analyzer is selected for the Industry Division Best Abstract Award Second Place. 

In the past year, Zybio keeps its academic research advancing, with global customers using Zybio's series of products having published more than 90 SCI academic articles on top international journals such as Immunity, National Science Review, and Military Medical Research, etc. Zybio, committed to innovation and academic advancement, sticks to development and progress, contributing to diagnostics and healthcare industry worldwide. 

Since 2018 when we started overseas business, Zybio has gradually set up offices in multiple countries and regions, as well as subsidiaries in Indonesia, Thailand, Philippines, Brazil, Mexico, Pakistan, Russia, Netherlands, etc. Currently, Zybio has over 300 engineers worldwide for an integrated Sales & Service system. The products, diagnostic solutions and services have been widely applied in over 20,000 healthcare facilities in 100 countries and regions in Asia, South America, North America, Europe and Africa.

Dedication to Accuracy, Zybio has been and will always be committed to improvement of total laboratory diagnostic solution and increasingly excellent products and services for partners. In this way, we aim to jointly facilitate the healthcare industry.